Oct 28, 2021 8:45am EDT CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
Oct 13, 2021 9:00am EDT CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
Sep 08, 2021 9:00am EDT CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)
Aug 10, 2021 4:04pm EDT CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 10, 2021 4:02pm EDT CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity